



December 16, 2012

Joseph Elliot, Ph.D.
Managing Director
Epitopoietic Research Corporation (ERC)
1055 E Colorado, Blvd., Suite 500
Pasadena, CA 91106
USA

Dear Dr. Elliot,

It was a pleasure to meet you at the Adult Brain Tumor Consortium meeting on December 10, 2012 in Baltimore. I very much enjoyed your presentation on ERC1671 and the highly encouraging preliminary results you described that have been obtained to date. I was particularly impressed with the results reported by my former fellow, Daniela Bota, MD, PhD, who now heads the neuro-oncology program at University of California, Irvine. I had the opportunity to see the data presented by Dr. Bota on ERC1671 at the Society for Neuro-Oncology meeting in November, 2012 in Washington, D.C.

As I indicated during our discussion in Baltimore, our group at the Dana-Farber Cancer Institute is extremely interested in advancing promising immunotherapy approaches for cancer patients. Specifically, I look forward to working with you and Dr. Stathopoulos to help develop ERC1671 for brain tumor patients in 2013.

Sincerely,



David A. Reardon, M.D.